Rimegepant: acute treatment for migraine headaches.

Pain Manag

Department of Pharmacy Practice, St. Louis College of Pharmacy, University of Health Sciences & Pharmacy in St Louis, 1 Pharmacy Place, St Louis, Missouri 63110, USA.

Published: May 2021

Migraine headache treatment is quickly evolving. There have been three new acute migraine treatment options (i.e., lasmiditan, rimegepant, ubrogepant) and four new preventive migraine treatment options (i.e., erenumab, fremanezumab, galcanezumab, eptinezumab) released in the past 3 years. The new migraine treatments are focusing on pathways within the newly, better understood neurovascular hypothesis that further describes the pathophysiology of migraine headaches in more detail than before. The discovery of vasoactive peptides, such as calcitonin gene-related peptide, has led to the development of many of these migraine agents. Rimegepant is one of these newly approved agents for acute migraine treatment in adults with or without aura. Rimegepant has been found to decrease pain and symptoms associated with migraine attacks and is generally well-tolerated.

Download full-text PDF

Source
http://dx.doi.org/10.2217/pmt-2020-0090DOI Listing

Publication Analysis

Top Keywords

migraine treatment
12
migraine
9
migraine headaches
8
acute migraine
8
treatment options
8
treatment
5
rimegepant
4
rimegepant acute
4
acute treatment
4
treatment migraine
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!